New Triple-Drug attack shows promise for tough breast cancer
NCT ID NCT05286437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II study is testing a combination of three drugs—lenvatinib, pembrolizumab, and letrozole—in people with advanced hormone receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy. The goal is to see if this combination can shrink tumors or slow disease progression. The study plans to enroll 40 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lenvatinib, Pembrolizumab, and Letrozole
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced breast cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a small, early-phase (phase II) study with only 40 participants. The combination may not work better than existing treatments, and side effects from the drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Centre Singapore
RECRUITINGSingapore, 169610, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••